Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Supriya Lifescience Ltd - 543434 - Statement Of Deviation Or Variation In The Use Of Proceeds Of The Fresh Issue Of The Initial Public Offer Of The Company

 Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended June 30, 2022 in the prescribed format. Further, we hereby confirm that there is no deviation or variation in the utilisation of IPO proceeds from the objects stated in the prospectus dated December 21, 2021. Kindly take the same on record and acknowledge the receipt.
12-08-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

 Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by ICICI Bank Limited, Monitoring Agency, for the quarter ended June 30, 2022 in respect of utilization of proceeds of the of the fresh issue of the IPO of the Company. Kindly take the same on record and acknowledge the receipt.
12-08-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s

 Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, August 12, 2022, inter-alia, has: 1. Considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2022. 2. Recommended re-appointment of M/s. Kakaria & Associates LLP, Chartered Accountants (Firm Registration No. 104558W/W100601) as the Statutory Auditors of the Company, for second term of five years from the conclusion of the ensuing 14th AGM till the conclusion of the 19th AGM to be held in the year 2027, subject to approval of the members at the ensuing 14th AGM..
12-08-2022
Bigul

Supriya Lifescience Ltd - 543434 - Unaudited Financial Results For The Quarter Ended June 30, 2022

 Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, August 12, 2022, inter-alia, has: 1. Considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2022. 2. Recommended re-appointment of M/s. Kakaria & Associates LLP, Chartered Accountants (Firm Registration No. 104558W/W100601) as the Statutory Auditors of the Company, for second term of five years from the conclusion of the ensuing 14th AGM till the conclusion of the 19th AGM to be held in the year 2027, subject to approval of the members at the ensuing 14th AGM..
12-08-2022
Bigul

Supriya Lifescience Ltd - 543434 - Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Friday, August 12, 2022, inter-alia, has: 1. Considered and approved the Unaudited Financial Results for the Quarter ended June 30, 2022. 2. Recommended re-appointment of M/s. Kakaria & Associates LLP, Chartered Accountants (Firm Registration No. 104558W/W100601) as the Statutory Auditors of the Company, for second term of five years from the conclusion of the ensuing 14th AGM till the conclusion of the 19th AGM to be held in the year 2027, subject to approval of the members at the ensuing 14th AGM..
12-08-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call will be held on Tuesday, August 16, 2022 at 3.00 P.M. IST to discuss operational and financial performance of the Company for the quarter ended June 30, 2022 (Q1 of FY 2022-23). The invite giving requisite details including the pre-registration link and dial-in details is attached herewith. This intimation is also being made available on the website of the Company at: https://supriyalifescience.com/investor-relation/ Kindly take the information on record.
06-08-2022
Bigul

Supriya Lifescience Ltd - 543434 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2022.

 Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2022 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2022. This is further to inform you that with reference to our letter dated June 29, 2022 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct for Prevention of Insider Trading, the ''Trading Window' for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Unaudited Financial Results for the quarter ended June 30, 2022. Kindly take the above said information on your records.
05-08-2022
Bigul

Supriya Lifescience Ltd - 543434 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith a duly signed Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 received from Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company for the quarter ended June 30, 2022. You are requested to kindly take the same on record.
08-07-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on July 8, 2022 via video conference. This is to further inform that the copy of the Investor Presentation has been uploaded on the Stock Exchanges and on the Company's website www.supriyalifescience.com for your information and for the information of your members and the public at large. This information is submitted to you pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Note: The above date is subject to change. Change may happen due to exigencies on the part of Company or Analyst/Investor/Fund. Request you to kindly take the same on record.
08-07-2022
Bigul

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to the relevant provisions of the SEBI Listing Regulations, we would like to inform you that the officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on July 6, 2022 via video conference. This is to further inform that the copy of the Investor Presentation has been uploaded on the Stock Exchanges and on the Company's website www.supriyalifescience.com for your information and for the information of your members and the public at large. This information is submitted to you pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Note: The above date is subject to change. Change may happen due to exigencies on the part of Company or Analyst/Investor/Fund. Request you to kindly take the same on record.
06-07-2022
Next Page
Close

Let's Open Free Demat Account